Detalhe da pesquisa
1.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516102
2.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27179402
3.
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
J Clin Oncol
; 35(26): 3030-3038, 2017 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28437161